Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Sae Hamaya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2805-2805
Open Access | Times Cited: 25

Showing 25 citing articles:

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review
Nilesh Kumar Sharma, Anjali Bahot, Gopinath Sekar, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 680-680
Open Access | Times Cited: 15
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Y. Qin, Shisong Han, Yahan Yu, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1808-1831
Closed Access | Times Cited: 10
Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1166-1166
Open Access | Times Cited: 21
Drug resistance in TKI therapy for hepatocellular carcinoma: mechanisms and strategies
Xue Jiang, Xiaoying Ge, Yueying Huang, et al.
Cancer Letters (2025), pp. 217472-217472
Closed Access
To construct and validate a risk score model of angiogenesis-related genes to predict the prognosis of hepatocellular carcinoma
Duangui Gao, Lu Yuan, Tianpeng Jiang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Extraction, GC-MS analysis, cytotoxic, anti-inflammatory and anticancer potential of Cannabis sativa female flower; in vitro, in vivo and in silico
Waqas Safir, Arif Malik, Haleema Saadia, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Uncovering the heterogeneity of NK cells on the prognosis of HCC by integrating bulk and single-cell RNA-seq data
Jiashuo Li, Zhenyi Liu, Gongming Zhang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight
Anqi Li, Rui Wang, Yu-Qiang Zhao, et al.
Metabolites (2024) Vol. 14, Iss. 6, pp. 325-325
Open Access | Times Cited: 3
Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System
Haiqing Wang, Wentao Bo, Xielin Feng, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 5581-5603
Open Access | Times Cited: 3
Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials
Qichuan Deng, Yü Huang, Jing Zeng, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117343-117343
Open Access | Times Cited: 3
Identification of differentially expressed mRNA/lncRNA modules in acutely regorafenib-treated sorafenib-resistant Huh7 hepatocellular carcinoma cells
Mina Baek, Minjae Kim, Hae In Choi, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0301663-e0301663
Open Access | Times Cited: 2
The Dual Role of LncRNAs in Hepatocellular Carcinoma: Friend and Foe
Farzaneh Abam, ‪Saeid Ghorbian
Gastroenterology & Endoscopy (2024) Vol. 2, Iss. 4, pp. 186-195
Open Access | Times Cited: 2
Identification of subclusters and prognostic genes based on glycolysis/gluconeogenesis in hepatocellular carcinoma
Dan Chen, Ayinuer Aierken, Hui Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma
Guangming Xu, Yifan Jiang, Yu Li, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 18, pp. 16261-16277
Closed Access | Times Cited: 5
Combating drug resistance in hepatocellular carcinoma: No awareness today, no action tomorrow
Fanbo Jing, Xiao Li, Hui Jiang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115561-115561
Open Access | Times Cited: 5
Genetic screening of liver cancer: State of the art
Milena Peruhova, Sonya Banova-Chakarova, Dimitrina Georgieva Miteva, et al.
World Journal of Hepatology (2024) Vol. 16, Iss. 5, pp. 716-730
Open Access | Times Cited: 1
Constructing an immune-related prognostic signature for predicting prognosis and immune response in hepatocellular carcinoma
Lichao Cao, Deliang Huang, Shenrui Zhang, et al.
Heliyon (2024) Vol. 10, Iss. 13, pp. e34012-e34012
Open Access | Times Cited: 1
Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors
Saade Abdalkareem Jasim, Abdulrahman T. Ahmed, Aziz Kubaev, et al.
Medical Oncology (2024) Vol. 41, Iss. 11
Closed Access | Times Cited: 1
An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma
Xiang’an Wu, Bao Jin, Xiao Liu, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 12, pp. 10319-10333
Closed Access | Times Cited: 3
Will AMPK be a potential therapeutic target for hepatocellular carcinoma?
Guo Chen, Mingyuan Li, Jingyi Yang, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 7, pp. 3241-3258
Open Access
NOTCH1 regulates the DNA damage response and sorafenib resistance by activating ATM in hepatocellular carcinoma
Jing Liu, Yan Yu, Bin Xu, et al.
American Journal of Translational Research (2024) Vol. 16, Iss. 12, pp. 7317-7329
Closed Access
Regorafenib for patients with progression of advanced hepatocellular carcinoma after treatment with atezolizumab plus bevacizumab: a case series
Wendi Kang, Hongjiang Fu, Yingen Luo, et al.
Journal of Gastrointestinal Oncology (2024) Vol. 15, Iss. 2, pp. 780-787
Open Access
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study
Ying Zhang, Kazushi Numata, Kento Imajo, et al.
Hepatology Research (2024) Vol. 54, Iss. 12, pp. 1174-1192
Closed Access
Prognostic modeling of hepatocellular carcinoma based on T-cell proliferation regulators: a bioinformatics approach
Hai Long, Xiao-Yang Bai, Xia Luo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Targeting MicroRNA Methylation: Innovative Approaches to Diagnosing and Treating Hepatocellular Carcinoma
Albert Sufianov, Murad Agaverdiev, Andrey Mashkin, et al.
Non-coding RNA Research (2024) Vol. 11, pp. 150-157
Open Access
Page 1

Scroll to top